AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28043903 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 1092
Study 25887569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 24
Study 25887569 — intervention group
Group type: COMPARATOR
Intervention: Simple discectomy
Number of subjects: 24
Study 23213075 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS (molecular adsorbent recirculating system)
Number of subjects: 189
Study 23213075 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (SMT)
Number of subjects: 189
Study 21887259 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-bore MR scanner
Number of subjects: 174
Study 21887259 — intervention group
Group type: COMPARATOR
Intervention: Open MR scanner
Number of subjects: 174
Study 19075102 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg/d
Number of subjects: 60
Study 19075102 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin/ezetimibe 10/10 mg/d
Number of subjects: 60
Study 19075102 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 17824295 — intervention group
Group type: EXPERIMENTAL
Intervention: Carni Q-gel (2250 mg/d L-carnitine and 270 mg/d hydrosoluble ubiquinol) for 12 weeks
Number of subjects: 62
Study 17824295 — intervention group
Group type: EXPERIMENTAL
Intervention: Carni Q-gel
Number of subjects: 62
Study 15648726 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary task that competes for left hemisphere resources
Number of subjects: 0
Study 15648726 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hemisphere task
Number of subjects: 0
Study 15648726 — intervention group
Group type: EXPERIMENTAL
Intervention: Misunderstanding of randomness
Number of subjects: 0
Study 12017230 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct family supervision (group 1, 7 children)
Number of subjects: 12
Study 12017230 — intervention group
Group type: COMPARATOR
Intervention: No direct supervision by a family caregiver (group 2, 5 children)
Number of subjects: 12
Study 9793589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/5 mL with normal breakfast (fat content 21 g)
Number of subjects: 10
Study 9793589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone suspension 750 mg/5 mL with Sustacal Plus (fat content 28 g)
Number of subjects: 10
Study 9793589 — intervention group
Group type: COMPARATOR
Intervention: Atovaquone suspension 750 mg/5 mL fasting
Number of subjects: 10
Study 7853041 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract in intensive care units
Number of subjects: 36
Study 7853041 — intervention group
Group type: COMPARATOR
Intervention: Including a paper written in German
Number of subjects: 36
Study 2239163 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nail (Rydell)
Number of subjects: 410
Study 2239163 — intervention group
Group type: COMPARATOR
Intervention: Two hook-pins (LIH)
Number of subjects: 410
Study 408142 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose on day 4 (n = 6)
Number of subjects: 37
Study 408142 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg glucagon with glucose load on day 4 (n = 5)
Number of subjects: 37
Study 408142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon with glucose load on day 4 (n = 6)
Number of subjects: 37
Study 408142 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infused alone on day 4 of fast (n = 5)
Number of subjects: 37
Study 408142 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon administered 24 h after glucose load (n = 6)
Number of subjects: 37
Study 31707788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31707788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 28589231 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB)
Number of subjects: 135
Study 28589231 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty (POBA)
Number of subjects: 135
Study 26051429 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive leaf extract (OLE) (51 mg oleuropein; 10 mg HT)
Number of subjects: 18
Study 26051429 — intervention group
Group type: COMPARATOR
Intervention: Matched control
Number of subjects: 18
Study 23644088 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional side branch (SB) stenting
Number of subjects: 413
Study 23644088 — intervention group
Group type: COMPARATOR
Intervention: Main vessel (MV) and side branch (SB) stenting
Number of subjects: 413
Study 21083582 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 50 mg
Number of subjects: 12
Study 21083582 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg
Number of subjects: 12
Study 21083582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19690227 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 4
Study 19690227 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand use of antibiotics
Number of subjects: 4
Study 17224857 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg drospirenone/1 mg estradiol (DRSP/E2)
Number of subjects: 36
Study 17224857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15129751 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrounding frames (various types including squares, parallel lines, squares with gaps, and squares with circular contours)
Number of subjects: 0
Study 15129751 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not explicitly defined in the abstract)
Number of subjects: 0
Study 11885213 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient women-centered substance abuse treatment program
Number of subjects: 15
Study 9782691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (treatment group)
Number of subjects: 133
Study 9782691 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacy care (control group)
Number of subjects: 133
Study 7869251 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (nitric oxide synthase blocker)
Number of subjects: 0
Study 7869251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 7869251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine + L-NMMA
Number of subjects: 0
Study 7869251 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral forearm without treatment)
Number of subjects: 0
Study 3044476 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 fractions per week
Number of subjects: 411
Study 3044476 — intervention group
Group type: COMPARATOR
Intervention: 2 fractions per week
Number of subjects: 411
Study 3044476 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 fractions
Number of subjects: 411
Study 3044476 — intervention group
Group type: COMPARATOR
Intervention: 12 fractions
Number of subjects: 411
Study 31102326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 572
Study 31102326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 572
Study 31102326 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1-3 mg/day)
Number of subjects: 572
Study 31129812 — intervention group
Group type: EXPERIMENTAL
Intervention: L-selenomethionine (L-Se-Met) 83 mcg/day
Number of subjects: 45
Study 31129812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 45
Study 28412086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolysis
Number of subjects: 803
Study 26056515 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular beer (up to 660 ml) followed by water ad-libitum (BW)
Number of subjects: 16
Study 26056515 — intervention group
Group type: COMPARATOR
Intervention: Mineral water ad-libitum (W)
Number of subjects: 16
Study 24335629 — intervention group
Group type: EXPERIMENTAL
Intervention: SECURE-C Cervical Artificial Disc
Number of subjects: 380
Study 24335629 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 380
Study 21659972 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg once a week) + 600 mg calcium + 400 IU vitamin D
Number of subjects: 80
Study 21659972 — intervention group
Group type: COMPARATOR
Intervention: Control (600 mg calcium + 400 IU vitamin D)
Number of subjects: 80
Study 19191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone (GnRH) analogues
Number of subjects: 40
Study 19191779 — intervention group
Group type: COMPARATOR
Intervention: Triple tourniquets
Number of subjects: 40
Study 16534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 9193
Study 16534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based regimen
Number of subjects: 9193
Study 16534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 9193
Study 16534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression or absence of ECG LVH by CP in patients without diabetes
Number of subjects: 9193
Study 16534012 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of ECG LVH in patients with diabetes
Number of subjects: 9193
Study 12969167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril, 10 mg/day
Number of subjects: 44
Study 12969167 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study 11015481 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acid (Mono) diet
Number of subjects: 19
Study 11015481 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate (CHO) diet
Number of subjects: 19
Study 8823331 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321 250 micrograms/m2/d
Number of subjects: 13
Study 8823331 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321 500 micrograms/m2/d
Number of subjects: 13
Study 8823331 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321 750 micrograms/m2/d
Number of subjects: 13
Study 1333909 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension injection alone (A, n = 54)
Number of subjects: 180
Study 1333909 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension injection + TAE using gelatin sponge (B, n = 29)
Number of subjects: 180
Study 1333909 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE followed by suspension injection (C, n = 34)
Number of subjects: 180
Study 1333909 — intervention group
Group type: COMPARATOR
Intervention: TAE alone (D, n = 63)
Number of subjects: 180
Study 1333909 — intervention group
Group type: COMPARATOR
Intervention: Regimen A vs Regimen D for tumors ≥ 5 cm
Number of subjects: 180
Study 1333909 — intervention group
Group type: COMPARATOR
Intervention: Regimen A vs Regimen D for tumors < 5 cm
Number of subjects: 180
Study 6385745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nasogastric tube feedings
Number of subjects: 40
Study 6385745 — intervention group
Group type: COMPARATOR
Intervention: Optimal oral nutrition
Number of subjects: 40
Study 29793970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile mindfulness programme
Number of subjects: 80
Study 29793970 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone mindfulness programme
Number of subjects: 80
Study 29793970 — intervention group
Group type: COMPARATOR
Intervention: Education programme
Number of subjects: 80
Study 29324495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (2 mg/kg for 15 minutes followed by 2 mg/kg/h)
Number of subjects: 135
Study 29324495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (20 mg/kg over 15 minutes followed by 20 mg/kg/h)
Number of subjects: 135
Study 29324495 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 135
Study 26792372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Zoledronic acid
Number of subjects: 251
Study 23737075 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care programme (n=93)
Number of subjects: 185
Study 23737075 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=92)
Number of subjects: 185
Study 22697439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness skills training intervention (4 sessions over 21 days)
Number of subjects: 53
Study 22697439 — intervention group
Group type: COMPARATOR
Intervention: No-intervention (control) condition
Number of subjects: 53
Study 20080983 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil, 400 mg
Number of subjects: 20
Study 20080983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18852662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 106
Study 18852662 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 106
Study 12575396 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) combined with captopril (CAP)
Number of subjects: 109
Study 12575396 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone and interferon (Control)
Number of subjects: 109
Study 9394054 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive coaching and interventions over the course of the academic year
Number of subjects: 0
Study 9394054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supportive coaching)
Number of subjects: 0
Study 7893247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Attachment Interview (AAI)
Number of subjects: 62
Study 2439255 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 17
Study 2439255 — intervention group
Group type: COMPARATOR
Intervention: Dextran‐40
Number of subjects: 17
Study 2439255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative colloids (0.5 g/kg)
Number of subjects: 17
Study 2439255 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate urinary onset patients
Number of subjects: 17
Study 2439255 — intervention group
Group type: COMPARATOR
Intervention: Delayed urinary onset patients
Number of subjects: 17
Study 31355931 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 153
Study 31355931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 29101402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (n=102) at an initial dose of 50 mg/d, escalated to a maximum of 200 mg/d for 12 weeks
Number of subjects: 201
Study 29101402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=99) for 12 weeks
Number of subjects: 201
Study 29101402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (n=102)
Number of subjects: 201
Study 29101402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=99)
Number of subjects: 201
Study 25568414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific cutting guides (PSCG)
Number of subjects: 140
Study 25568414 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation (CI)
Number of subjects: 140
Study 23293335 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (1 infusion)
Number of subjects: 1367
Study 23293335 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (3 infusions)
Number of subjects: 1367
Study 20825367 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO 80 p.p.m. + GC (2mg/kg, hydrocortisone)
Number of subjects: 15
Study 20825367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrogen) + GC (2mg/kg, hydrocortisone)
Number of subjects: 15
Study 18288090 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for up to 14 weeks
Number of subjects: 1554
Study 18288090 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-step treatment after citalopram
Number of subjects: 1554
Study 18288090 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-step treatment among those with unsatisfactory benefit to citalopram and one next-step pharmacotherapy
Number of subjects: 1554
Study 16547529 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-based immunomodulatory agents (e.g. intravenous immunoglobulin, thalidomide, pentoxifylline)
Number of subjects: 0
Study 16547529 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled mortality studies
Number of subjects: 0
Study 12615589 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage intervention comprising screening and a brief standardized nursing assessment and referral.
Number of subjects: 345
Study 12615589 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 345
Study 10967260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 30
Study 10967260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactococcus lactis
Number of subjects: 30
Study 10967260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ethyl cellulose)
Number of subjects: 30
Study 9189647 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean products
Number of subjects: 34
Study 9189647 — intervention group
Group type: COMPARATOR
Intervention: Skim milk products and soy oil
Number of subjects: 34
Study 9189647 — intervention group
Group type: COMPARATOR
Intervention: 2% cows' milk products
Number of subjects: 34
Study 1439112 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (Tp-1) treatment
Number of subjects: 19
Study 1439112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study 29239030 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight neuromuscular exercises (EG, n = 86)
Number of subjects: 160
Study 29239030 — intervention group
Group type: COMPARATOR
Intervention: Standard tactical-technical exercises (CG, n = 74)
Number of subjects: 160
Study 27557913 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (Cervitec Plus) applied after resin infiltration (DMG, ICON)
Number of subjects: 45
Study 27557913 — intervention group
Group type: COMPARATOR
Intervention: Resin infiltration (DMG, ICON) without chlorhexidine varnish
Number of subjects: 45
Study 25904773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glucose regimen (Physioneal, Extraneal, Nutrineal)
Number of subjects: 80
Study 25904773 — intervention group
Group type: COMPARATOR
Intervention: Dianeal (control group)
Number of subjects: 80
Study 24336664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy (10 sessions)
Number of subjects: 94
Study 20513116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (long-term exposure)
Number of subjects: 0
Study 17997712 — intervention group
Group type: EXPERIMENTAL
Intervention: Finite element analysis (FEA) assessing bone mechanical properties, volumetric bone density, and microarchitecture
Number of subjects: 66
Study 17997712 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal components analysis (PCA)
Number of subjects: 66
Study 17997712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mechanical properties assessed by microFE
Number of subjects: 66
Study 16946640 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific spinal stabilization exercises
Number of subjects: 97
Study 16946640 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 97
Study 12904183 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 and 1.0 MAC)
Number of subjects: 36
Study 12904183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 and 1.0 MAC)
Number of subjects: 36
Study 12904183 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (0.5 and 1.0 MAC)
Number of subjects: 36
Study 10673735 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antihypertensive agents (amlodipine and perindopril)
Number of subjects: 0
Study 10673735 — intervention group
Group type: COMPARATOR
Intervention: Older antihypertensive agents (bendroflumethiazide and atenolol)
Number of subjects: 0
Study 9104123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cairwave Therapy System
Number of subjects: 12
Study 9104123 — intervention group
Group type: COMPARATOR
Intervention: Airwave mattress
Number of subjects: 12
Study 1490203 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rh‐Epo)
Number of subjects: 28
Study 3886122 — intervention group
Group type: EXPERIMENTAL
Intervention: 34.5 Gy of radiotherapy (in 19 days overall) followed by surgery
Number of subjects: 410
Study 3886122 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 410
Study 3886122 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy
Number of subjects: 410
Study 3886122 — intervention group
Group type: COMPARATOR
Intervention: Both therapeutic regimens
Number of subjects: 410
Study 31584782 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol 0.01% lotion
Number of subjects: 234
Study 31584782 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 234
Study 30334410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective cervical nerve root block
Number of subjects: 60
Study 30334410 — intervention group
Group type: COMPARATOR
Intervention: X-ray C-arm-guided cervical spinal block
Number of subjects: 60
Study 27181998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 744
Study 27181998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily (S100)
Number of subjects: 744
Study 27181998 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily (M1000)
Number of subjects: 744
Study 27181998 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily (M1700)
Number of subjects: 744
Study 27181998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice daily plus Metformin 500 mg twice daily (S100/M1000)
Number of subjects: 744
Study 27181998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice daily plus Metformin 850 mg twice daily (S100/M1700)
Number of subjects: 744
Study 27181998 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 744
Study 27181998 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metformin groups
Number of subjects: 744
Study 24254248 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cancer-related direct-to-consumer advertising (DTCA)
Number of subjects: 0
Study 22574560 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRRT (SLEDD)
Number of subjects: 60